

# 2017-2022 Global and Japan Antineoplastic Drugs of Tinib Class Market Analysis Report

<https://marketpublishers.com/r/221C1C6BDCCEN.html>

Date: August 2017

Pages: 113

Price: US\$ 3,085.00 (Single User License)

ID: 221C1C6BDCCEN

## Abstracts

The global Antineoplastic Drugs of Tinib Class market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Antineoplastic Drugs of Tinib Class market's development status and future trend in the global and Japan. It splits Antineoplastic Drugs of Tinib Class market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include

AstraZeneca K.K.

Bristol-Myers Squibb

Chugai Pharmaceutical Co., Ltd.

DAIICHI SANKYO ESPHA CO., LTD.

Elmed Eisai Co., Ltd.

Meiji Seika Pharma Co., Ltd.

Nichi-iko Pharmaceutical Co.,Ltd

NIPPON KAYAKU

NIPRO CORPORATION

Novartis Pharma K.K.

OHARA Pharmaceutical Co.,Ltd.

Pfizer Pharmaceuticals Inc.

Sanofi K.K.

TOWA PHARMACEUTICAL CO., LTD.

Geographically, this report splits the Global market into the following regions:

Asia Pacific

Japan

Tokyo

Yokohama

Osaka

Nagoya

Others

China

Korea

India

Others

Europe

France

Germany

United Kingdom

Italy

Russia

Others

North America

United States

Canada

Latin America

Brazil

Mexico

Others

Southeast Asia

Singapore

Malaysia

Vietnam

Myanmar

Thailand

Indonesia

Philippines

Others

Middle East & Africa

Saudi Arabia

Iran

UAE

Turkey

Israel

Egypt

South Africa

Others

On the basis of product, the Antineoplastic Drugs of Tinib Class market is primarily split into

Antineoplastic Drugs of Tinib Class Market, by Tinib Class

Gefitinib

Imatinib

Nilotinib

Lapatinib

Telatinib

Sunitinib

Erlotinib

Neratinib

Dasatinib

Bosutinib

Axitinib

Vandetanib

Canertinib

Afatinib

## Key Applications

Oncology Department

Department of Chemotherapy

Pharmacology

## Contents

### 1 ANTINEOPLASTIC DRUGS OF TINIB CLASS OVERVIEW

1.1 Product Overview and Scope of Antineoplastic Drugs of Tinib Class

1.2 Global and Japan Antineoplastic Drugs of Tinib Class Market by Applications/End Users

1.2.1 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

1.2.1.1 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share by Applications (2012-2017)

1.2.1.2 Japan Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) by Applications (2012-2017)

1.2.1.3 Market Drivers and Opportunities

1.2.2 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

1.2.3 Global Antineoplastic Drugs of Tinib Class Sales by Application (2012-2017)

1.2.3.1 Global Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share by Applications (2012-2017)

1.2.3.2 Global Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) by Applications (2012-2017)

1.2.3.3 Market Drivers and Opportunities

1.2.4 Global Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share Comparison by Applications (2012-2017)

1.2.5 Oncology Department

1.2.6 Department of Chemotherapy

1.2.7 Pharmacology

1.3 Global and Japan Market Size (Sales and Revenue) of Antineoplastic Drugs of Tinib Class (2012-2017)

1.3.1 Japan Market Size (Sales and Revenue) of Antineoplastic Drugs of Tinib Class (2012-2017)

1.3.1.1 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Growth Rate (%) (2012-2017)

1.3.1.2 Japan Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Growth Rate (2012-2017)

1.3.2 Global Market Size (Sales and Revenue) of Antineoplastic Drugs of Tinib Class (2012-2017)

1.3.2.1 Global Antineoplastic Drugs of Tinib Class Sales ( ) and Growth Rate (%) (2012-2017)

1.3.2.2 Global Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Growth Rate (2012-2017)

1.4 Global and Japan Classification of Antineoplastic Drugs of Tinib Class by Tinib Class

1.4.1 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share by Tinib Class (2012-2017)

1.4.2 Global Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share by Tinib Class (2012-2017)

1.4.3 Japan Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share by Tinib Class (2012-2017)

1.4.4 Global Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share by Tinib Class (2012-2017)

1.4.5 Japan Antineoplastic Drugs of Tinib Class Price ( ) by Tinib Class (2012-2017)

1.4.6 Global Antineoplastic Drugs of Tinib Class Price ( ) by Tinib Class (2012-2017)

1.4.7 Japan Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) by Tinib Class (2012-2017)

1.4.8 Global Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) by Tinib Class (2012-2017)

1.4.9 Gefitinib

1.4.10 Imatinib

1.4.11 Nilotinib

1.4.12 Lapatinib

1.4.13 Telatinib

Sunitinib

Erlotinib

Neratinib

Dasatinib

Bosutinib

Axitinib

Vandetanib

Canertinib

Afatinib

## **2 GLOBAL AND JAPAN ANTINEOPLASTIC DRUGS OF TINIB CLASS MARKET COMPETITION BY PLAYERS/MANUFACTURERS**

2.1 Japan Antineoplastic Drugs of Tinib Class Market Competition by Players/Manufacturers

2.1.1 Japan Antineoplastic Drugs of Tinib Class Sales and Market Share of Key

Players/Manufacturers (2012-2017)

2.1.2 Japan Antineoplastic Drugs of Tinib Class Revenue and Share by

Players/Manufacturers (2012-2017)

2.1.3 Japan Antineoplastic Drugs of Tinib Class Average Price ( ) by

Players/Manufacturers (2012-2017)

2.1.4 Japan Antineoplastic Drugs of Tinib Class Market Competitive Situation and Trends

2.1.4.1 Japan Antineoplastic Drugs of Tinib Class Market Concentration Rate

2.1.4.2 Japan Antineoplastic Drugs of Tinib Class Market Share of Top 3 and Top 5

Players/Manufacturers

2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market

2.1.5 Japan Players/Manufacturers Antineoplastic Drugs of Tinib Class Manufacturing Base Distribution, Sales Area, Product Types

2.2 Global Antineoplastic Drugs of Tinib Class Market Competition by Players/Manufacturers

2.2.1 Global Antineoplastic Drugs of Tinib Class Sales and Market Share of Key Players/Manufacturers (2012-2017)

2.2.2 Global Antineoplastic Drugs of Tinib Class Revenue and Share by Players/Manufacturers (2012-2017)

2.2.3 Global Antineoplastic Drugs of Tinib Class Average Price ( ) by Players/Manufacturers (2012-2017)

2.2.4 Global Antineoplastic Drugs of Tinib Class Market Competitive Situation and Trends

2.2.4.1 Global Antineoplastic Drugs of Tinib Class Market Concentration Rate

2.2.4.2 Global Antineoplastic Drugs of Tinib Class Market Share of Top 3 and Top 5

Players/Manufacturers

2.2.4.3 Mergers & Acquisitions, Expansion in Global Market

2.2.5 Global Players/Manufacturers Antineoplastic Drugs of Tinib Class Manufacturing Base Distribution, Sales Area, Product Types

### **3 GLOBAL AND JAPAN ANTINEOPLASTIC DRUGS OF TINIB CLASS SALES AND REVENUE BY REGIONS (2012-2017)**

3.1 Asia Pacific Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)

3.1.1 Japan Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.1.1.1 Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.1.1.2 Japan Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market



## Share (2012-2017)

3.1.1.3 Japan Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.1.2 China Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.1.2.1 China Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.1.2.2 China Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.1.2.3 China Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.1.3 Korea Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.1.3.1 Korea Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.1.3.2 Korea Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.1.3.3 Korea Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.1.4 India Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.1.4.1 India Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.1.4.2 India Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.1.4.3 India Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.1.5 Others Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.1.5.1 Others Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.1.5.2 Others Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.1.5.3 Others Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.2 Europe Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)

3.2.1 France Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.2.1.1 France Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.2.1.2 France Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.2.1.3 France Antineoplastic Drugs of Tinib Class Price (})(2012-2017)

3.2.2 Germany Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.2.2.1 Germany Antineoplastic Drugs of Tinib Class Sales (}) and Market Share (2012-2017)

3.2.2.2 Germany Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

- 3.2.2.3 Germany Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
- 3.2.3 United Kingdom Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
  - 3.2.3.1 United Kingdom Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
  - 3.2.3.2 United Kingdom Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)
  - 3.2.3.3 United Kingdom Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
- 3.2.4 Italy Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
  - 3.2.4.1 Italy Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
  - 3.2.4.2 Italy Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)
  - 3.2.4.3 Italy Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
- 3.2.5 Russia Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
  - 3.2.5.1 Russia Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
  - 3.2.5.2 Russia Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)
  - 3.2.5.3 Russia Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
- 3.2.6 Others Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
  - 3.2.6.1 Others Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
  - 3.2.6.2 Others Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)
  - 3.2.6.3 Others Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
- 3.3 North America Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)
  - 3.3.1 United States Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
    - 3.3.1.1 United States Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
    - 3.3.1.2 United States Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)
    - 3.3.1.3 United States Antineoplastic Drugs of Tinib Class Price (€)(2012-2017)
  - 3.3.2 Canada Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)
    - 3.3.2.1 Canada Antineoplastic Drugs of Tinib Class Sales (€) and Market Share (2012-2017)
    - 3.3.2.2 Canada Antineoplastic Drugs of Tinib Class Revenue (Million USD) and

## Market Share (2012-2017)

3.3.2.3 Canada Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

## 3.4 Latin America Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)

3.4.1 Brazil Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.4.1.1 Brazil Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.4.1.2 Brazil Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.4.1.3 Brazil Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

3.4.2 Mexico Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.4.2.1 Mexico Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.4.2.2 Mexico Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.4.2.3 Mexico Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

3.4.3 Others Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.4.3.1 Others Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.4.3.2 Others Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.4.3.3 Others Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

## 3.5 Southeast Asia Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)

3.5.1 Singapore Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.1.1 Singapore Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.1.2 Singapore Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.1.3 Singapore Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

3.5.2 Malaysia Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.2.1 Malaysia Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.2.2 Malaysia Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.2.3 Malaysia Antineoplastic Drugs of Tinib Class Price ()/(2012-2017)

3.5.3 Vietnam Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.3.1 Vietnam Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.3.2 Vietnam Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.3.3 Vietnam Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.5.4 Myanmar Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.4.1 Myanmar Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.4.2 Myanmar Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.4.3 Myanmar Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.5.5 Thailand Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.5.1 Thailand Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.5.2 Thailand Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.5.3 Thailand Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.5.6 Indonesia Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.6.1 Indonesia Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.6.2 Indonesia Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.6.3 Indonesia Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.5.7 Philippines Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.7.1 Philippines Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.7.2 Philippines Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.7.3 Philippines Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.5.8 Others Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.5.8.1 Others Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.5.8.2 Others Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.5.8.3 Others Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6 Middle East & Africa Antineoplastic Drugs of Tinib Class Sales and Revenue by Regions (2012-2017)

3.6.1 Saudi Arabia Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.1.1 Saudi Arabia Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.1.2 Saudi Arabia Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.1.3 Saudi Arabia Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.2 Iran Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.2.1 Iran Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.2.2 Iran Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.2.3 Iran Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.3 UAE Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.3.1 UAE Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.3.2 UAE Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.3.3 UAE Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.4 Turkey Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.4.1 Turkey Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.4.2 Turkey Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.4.3 Turkey Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.5 Israel Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.5.1 Israel Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.5.2 Israel Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.5.3 Israel Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.6 Egypt Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.6.1 Egypt Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.6.2 Egypt Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.6.3 Egypt Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.7 South Africa Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.7.1 South Africa Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.7.2 South Africa Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)



3.6.7.3 South Africa Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

3.6.8 Others Antineoplastic Drugs of Tinib Class Sales and Revenue (2012-2017)

3.6.8.1 Others Antineoplastic Drugs of Tinib Class Sales ( ) and Market Share (2012-2017)

3.6.8.2 Others Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Market Share (2012-2017)

3.6.8.3 Others Antineoplastic Drugs of Tinib Class Price ( )(2012-2017)

## **4 GLOBAL AND JAPAN ANTINEOPLASTIC DRUGS OF TINIB CLASS PLAYERS/MANUFACTURERS PROFILES AND SALES DATA**

4.1 AstraZeneca K.K.

4.1.1 Company Basic Information, Manufacturing Base and Competitors

4.1.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.1.2.1 Product A

4.1.2.2 Product B

4.1.3 AstraZeneca K.K. Antineoplastic Drugs of Tinib Class Sales ( ), Revenue (Million USD), Price ( ) and Gross Margin ( %)(2012-2017)

4.1.4 Main Business/Business Overview

4.2 Bristol-Myers Squibb

4.2.1 Company Basic Information, Manufacturing Base and Competitors

4.2.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.2.2.1 Product A

4.2.2.2 Product B

4.2.3 Bristol-Myers Squibb Antineoplastic Drugs of Tinib Class Sales ( ), Revenue (Million USD), Price ( ) and Gross Margin ( %)(2012-2017)

4.2.4 Main Business/Business Overview

4.3 Chugai Pharmaceutical Co., Ltd.

4.3.1 Company Basic Information, Manufacturing Base and Competitors

4.3.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.3.2.1 Product A

4.3.2.2 Product B

4.3.3 Chugai Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Sales ( ), Revenue (Million USD), Price ( ) and Gross Margin ( %)(2012-2017)

4.3.4 Main Business/Business Overview

4.4 DAIICHI SANKYO ESPHA CO., LTD.

- 4.4.1 Company Basic Information, Manufacturing Base and Competitors
- 4.4.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification
  - 4.4.2.1 Product A
  - 4.4.2.2 Product B
- 4.4.3 DAIICHI SANKYO ESPHA CO., LTD. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
- 4.4.4 Main Business/Business Overview
- 4.5 Elmed Eisai Co., Ltd.
  - 4.5.1 Company Basic Information, Manufacturing Base and Competitors
  - 4.5.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification
    - 4.5.2.1 Product A
    - 4.5.2.2 Product B
  - 4.5.3 Elmed Eisai Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
  - 4.5.4 Main Business/Business Overview
- 4.6 Meiji Seika Pharma Co., Ltd.
  - 4.6.1 Company Basic Information, Manufacturing Base and Competitors
  - 4.6.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification
    - 4.6.2.1 Product A
    - 4.6.2.2 Product B
  - 4.6.3 Meiji Seika Pharma Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
  - 4.6.4 Main Business/Business Overview
- 4.7 Nichi-iko Pharmaceutical Co., Ltd.
  - 4.7.1 Company Basic Information, Manufacturing Base and Competitors
  - 4.7.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification
    - 4.7.2.1 Product A
    - 4.7.2.2 Product B
  - 4.7.3 Nichi-iko Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
  - 4.7.4 Main Business/Business Overview
- 4.8 NIPPON KAYAKU
  - 4.8.1 Company Basic Information, Manufacturing Base and Competitors
  - 4.8.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.8.2.1 Product A

4.8.2.2 Product B

4.8.3 NIPPON KAYAKU Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.8.4 Main Business/Business Overview

4.9 NIPRO CORPORATION

4.9.1 Company Basic Information, Manufacturing Base and Competitors

4.9.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.9.2.1 Product A

4.9.2.2 Product B

4.9.3 NIPRO CORPORATION Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.9.4 Main Business/Business Overview

4.10 Novartis Pharma K.K.

4.10.1 Company Basic Information, Manufacturing Base and Competitors

4.10.2 Antineoplastic Drugs of Tinib Class Product Category, Application and Specification

4.10.2.1 Product A

4.10.2.2 Product B

4.10.3 Novartis Pharma K.K. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.10.4 Main Business/Business Overview

4.11 OHARA Pharmaceutical Co., Ltd.

4.12 Pfizer Pharmaceuticals Inc.

4.13 Sanofi K.K.

4.14 TOWA PHARMACEUTICAL CO., LTD.

## **5 ANTINEOPLASTIC DRUGS OF TINIB CLASS MANUFACTURING COST ANALYSIS**

5.1 Antineoplastic Drugs of Tinib Class Key Raw Materials Analysis

5.1.1 Key Raw Materials

5.1.2 Price Trend of Key Raw Materials

5.1.3 Key Suppliers of Raw Materials

5.1.4 Market Concentration Rate of Raw Materials

5.2 Proportion of Manufacturing Cost Structure

5.2.1 Raw Materials

5.2.2 Labor Cost



5.2.3 Manufacturing Expenses

5.3 Manufacturing Process Analysis of Antineoplastic Drugs of Tinib Class

## **6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

6.1 Antineoplastic Drugs of Tinib Class Industrial Chain Analysis

6.2 Upstream Raw Materials Sourcing

6.3 Raw Materials Sources of Antineoplastic Drugs of Tinib Class Major Players/Manufacturers in 2016

6.4 Downstream Buyers

## **7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

7.1 Marketing Channel

7.1.1 Direct Marketing

7.1.2 Indirect Marketing

7.1.3 Marketing Channel Development Trend

7.2 Market Positioning

7.2.1 Pricing Strategy

7.2.2 Brand Strategy

7.2.3 Target Client

7.3 Distributors/Traders List

## **8 MARKET EFFECT FACTORS ANALYSIS**

8.1 Technology Progress/Risk

8.1.1 Substitutes Threat

8.1.2 Technology Progress in Related Industry

8.2 Consumer Needs/Customer Preference Change

8.3 Economic/Political Environmental Change

## **9 GLOBAL AND JAPAN ANTINEOPLASTIC DRUGS OF TINIB CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)**

9.1 Global and Japan Antineoplastic Drugs of Tinib Class Sales ( ), Revenue (Million USD) Forecast (2017-2022)

9.2 Global and Japan Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Type (2017-2022)

9.2.1 by Tinib Class

9.2.2 by

9.3 Global and Japan Antineoplastic Drugs of Tinib Class Sales () Forecast by Application (2017-2022)

9.4 Global and Japan Antineoplastic Drugs of Tinib Class Sales () Forecast by Regions (2017-2022)

## **10 RESEARCH FINDINGS AND CONCLUSION**

## **11 METHODOLOGY AND DATA SOURCE**

11.1 Methodology/Research Approach

11.1.1 Research Programs/Design

11.1.2 Market Size Estimation

11.1.3 Market Breakdown and Data Triangulation

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Disclaimer

11.4 Author List

## List Of Tables

### LIST OF TABLES AND FIGURES

Figure Product Picture of Antineoplastic Drugs of Tinib Class

Table Japan Antineoplastic Drugs of Tinib Class Sales (Million Units) Comparison by Applications (2012-2017)

Figure Japan Sales Market Share (%) of Antineoplastic Drugs of Tinib Class by Applications in 2016

Table Global Antineoplastic Drugs of Tinib Class Sales (Million Units) Comparison by Applications (2012-2017)

Figure Global Sales Market Share (%) of Antineoplastic Drugs of Tinib Class by Applications in 2016

Figure Oncology Department Examples

Table Key Downstream Customer in Oncology Department

Figure Department of Chemotherapy Examples

Table Key Downstream Customer in Department of Chemotherapy

Figure Pharmacology Examples

Table Key Downstream Customer in Pharmacology

Figure Gefitinib Product Picture

Figure Imatinib Product Picture

Figure Nilotinib Product Picture

Figure Lapatinib Product Picture

Figure Telatinib Product Picture

Figure Product Picture

Figure Product Picture

Table AstraZeneca K.K. Basic Information List

Table AstraZeneca K.K. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table AstraZeneca K.K. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table AstraZeneca K.K. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure AstraZeneca K.K. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Bristol-Myers Squibb Antineoplastic Drugs of Tinib Class Sales Growth Rate

(%)(2012-2017)

Table Bristol-Myers Squibb Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Bristol-Myers Squibb Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Basic Information List

Table Chugai Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Chugai Pharmaceutical Co., Ltd. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table DAIICHI SANKYO ESPHA CO., LTD. Basic Information List

Table DAIICHI SANKYO ESPHA CO., LTD. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table DAIICHI SANKYO ESPHA CO., LTD. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table DAIICHI SANKYO ESPHA CO., LTD. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure DAIICHI SANKYO ESPHA CO., LTD. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Elmed Eisai Co., Ltd. Basic Information List

Table Elmed Eisai Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Elmed Eisai Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table Elmed Eisai Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Elmed Eisai Co., Ltd. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Meiji Seika Pharma Co., Ltd. Basic Information List

Table Meiji Seika Pharma Co., Ltd. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Meiji Seika Pharma Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table Meiji Seika Pharma Co., Ltd. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Meiji Seika Pharma Co., Ltd. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Basic Information List

Table Nichi-iko Pharmaceutical Co.,Ltd Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Nichi-iko Pharmaceutical Co.,Ltd Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table NIPPON KAYAKU Basic Information List

Table NIPPON KAYAKU Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table NIPPON KAYAKU Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table NIPPON KAYAKU Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure NIPPON KAYAKU Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table NIPRO CORPORATION Basic Information List

Table NIPRO CORPORATION Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table NIPRO CORPORATION Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table NIPRO CORPORATION Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure NIPRO CORPORATION Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table Novartis Pharma K.K. Basic Information List

Table Novartis Pharma K.K. Antineoplastic Drugs of Tinib Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Novartis Pharma K.K. Antineoplastic Drugs of Tinib Class Sales Growth Rate (%) (2012-2017)

Table Novartis Pharma K.K. Antineoplastic Drugs of Tinib Class Sales Market Share (%) in Japan (2012-2017)

Figure Novartis Pharma K.K. Antineoplastic Drugs of Tinib Class Revenue Market Share (%) in Japan (2012-2017)

Table OHARA Pharmaceutical Co.,Ltd. Basic Information List

Table Pfizer Pharmaceuticals Inc. Basic Information List  
Table Sanofi K.K. Basic Information List  
Table TOWA PHARMACEUTICAL CO., LTD. Basic Information List  
Table Production Base and Market Concentration Rate of Raw Material  
Figure Price Trend of Key Raw Materials  
Table Key Suppliers of Raw Materials  
Figure Manufacturing Cost Structure of Antineoplastic Drugs of Tinib Class  
Figure Manufacturing Process Analysis of Antineoplastic Drugs of Tinib Class  
Figure Antineoplastic Drugs of Tinib Class Industrial Chain Analysis  
Table Raw Materials Sources of Antineoplastic Drugs of Tinib Class Major Players/Manufacturers in 2016  
Table Major Buyers of Antineoplastic Drugs of Tinib Class  
Table Distributors/Traders List  
Figure Japan Antineoplastic Drugs of Tinib Class Sales ( ) and Growth Rate (%) Forecast (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Price ( ) Trend Forecast (2017-2022)  
Figure Global Antineoplastic Drugs of Tinib Class Sales ( ) and Growth Rate (%) Forecast (2017-2022)  
Figure Global Antineoplastic Drugs of Tinib Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)  
Figure Global Antineoplastic Drugs of Tinib Class Price ( ) Trend Forecast (2017-2022)  
Table Japan Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Type (2017-2022)  
Table Global Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Type (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Type (2017-2022)  
Figure Global Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Type (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Type in 2017  
Figure Global Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Type in 2017  
Table Japan Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Application (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Application (2017-2022)  
Figure Japan Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Application in 2017

Table Global Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Application (2017-2022)

Figure Global Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Application (2017-2022)

Figure Global Antineoplastic Drugs of Tinib Class Sales Volume Market Share Forecast by Application in 2017

Table Japan Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Regions (2017-2022)

Table Japan Antineoplastic Drugs of Tinib Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Japan Antineoplastic Drugs of Tinib Class Sales Volume Share Forecast by Regions (2017-2022)

Table Global Antineoplastic Drugs of Tinib Class Sales ( ) Forecast by Regions (2017-2022)

Table Global Antineoplastic Drugs of Tinib Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Antineoplastic Drugs of Tinib Class Sales Volume Share Forecast by Regions (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources



## I would like to order

Product name: 2017-2022 Global and Japan Antineoplastic Drugs of Tinib Class Market Analysis Report

Product link: <https://marketpublishers.com/r/221C1C6BDCCEN.html>

Price: US\$ 3,085.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/221C1C6BDCCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970